gp120: Biologic aspects of structural features
- PMID: 11244037
- DOI: 10.1146/annurev.immunol.19.1.253
gp120: Biologic aspects of structural features
Abstract
HIV-1 particles are decorated with a network of densely arranged envelope spikes on their surface. Each spike is formed of a trimer of heterodimers of the gp120 surface and the gp41 transmembrane glycoproteins. These molecules mediate HIV-1 entry into target cells, initiating the HIV-1 replication cycle. They are a target for entry-blocking drugs and for neutralizing Abs that could contribute to vaccine protection. The crystal structure of the core of gp120 has been recently solved. It reveals the structure of the conserved HIV-1 receptor binding sites and some of the mechanisms evolved by HIV-1 to escape Ab responses. The gp120 consists of three faces. One is largely inaccessible on the native trimer, and two faces are exposed but apparently have low immunogenicity, particularly on primary viruses. We have modeled HIV-1 neutralization by a CD4 binding site monoclonal Ab, and we propose that neutralization takes place by inhibition of the interaction between gp120 and the target cell membrane receptors as a result of steric hindrance. Knowledge of gp120 structure and function should assist in the design of new drugs as well as of an effective vaccine. In the latter case, circumventing the low immunogenicity of the HIV-1 envelope spike is a major challenge.
Similar articles
-
The antigenic structure of the HIV gp120 envelope glycoprotein.Nature. 1998 Jun 18;393(6686):705-11. doi: 10.1038/31514. Nature. 1998. PMID: 9641684
-
Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.Virology. 1997 Mar 17;229(2):360-9. doi: 10.1006/viro.1997.8443. Virology. 1997. PMID: 9126249
-
GP120: target for neutralizing HIV-1 antibodies.Annu Rev Immunol. 2006;24:739-69. doi: 10.1146/annurev.immunol.24.021605.090557. Annu Rev Immunol. 2006. PMID: 16551265 Review.
-
Crystal structure of a neutralizing human IGG against HIV-1: a template for vaccine design.Science. 2001 Aug 10;293(5532):1155-9. doi: 10.1126/science.1061692. Science. 2001. PMID: 11498595
-
Progress in targeting HIV-1 entry.Drug Discov Today. 2005 Aug 15;10(16):1085-94. doi: 10.1016/S1359-6446(05)03550-6. Drug Discov Today. 2005. PMID: 16182193 Review.
Cited by
-
Evolution of coreceptor utilization to escape CCR5 antagonist therapy.Virology. 2016 Jul;494:198-214. doi: 10.1016/j.virol.2016.04.010. Epub 2016 Apr 26. Virology. 2016. PMID: 27128349 Free PMC article.
-
Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.J Virol. 2003 Jan;77(1):642-58. doi: 10.1128/jvi.77.1.642-658.2003. J Virol. 2003. PMID: 12477867 Free PMC article.
-
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes.Proc Natl Acad Sci U S A. 2002 May 14;99(10):6913-8. doi: 10.1073/pnas.102562599. Epub 2002 May 7. Proc Natl Acad Sci U S A. 2002. PMID: 11997472 Free PMC article.
-
Inhibition of HIV Env binding to cellular receptors by monoclonal antibody 2G12 as probed by Fc-tagged gp120.Retrovirology. 2006 Jul 3;3:39. doi: 10.1186/1742-4690-3-39. Retrovirology. 2006. PMID: 16817962 Free PMC article.
-
Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design.J Virol. 2003 May;77(10):5889-901. doi: 10.1128/jvi.77.10.5889-5901.2003. J Virol. 2003. PMID: 12719582 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
